# Risvutatug rezetecan (ris-rez) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez

> The next catalyst for risvutatug rezetecan (ris-rez), sponsored by GSK plc (GSK), is its topline data readout, Nov 2027 to Feb 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | risvutatug rezetecan (ris-rez) |
| Codes |  |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Neoplasms, Lung](https://sec-api.dev/indications/neoplasms-lung), [Neoplasms, Prostate](https://sec-api.dev/indications/neoplasms-prostate) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Nov 2027 to Feb 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms, Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07099898 (A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07099898

### November 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms, Lung.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07099898 (A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07099898

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Neoplasms, Prostate.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07802704 (A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07802704

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Neoplasms, Prostate.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07802704 (A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07802704

Calendar months: [November 2027](https://sec-api.dev/fda-calendar/2027-11)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Risvutatug rezetecan (ris-rez) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez

```bibtex
@misc{secapidev_pdufa_risvutatug_rezetecan_ris_rez_20261116,
  title        = {Risvutatug rezetecan (ris-rez) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_risvutatug_rezetecan_ris_rez_20261116","title":"Risvutatug rezetecan (ris-rez) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/risvutatug-rezetecan-ris-rez","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
